Member State to which the notification was sent
Date of acknowledgement from the Member State Competent Authority
Title of the Project
Investigation of the genetically modified Thaumatin producing spring barley line ‘Malt-607-1001’ in field tests
Proposed period of release:
01/05/2008 to 01/05/2017
Name of the Institute(s) or Company(ies)
TAPTOP Tanácsadó Szolgáltató Bt., (‘TAPTOP’ Consulting Service Ltd. JSt. Co.) H-2100 Gödöllő, Fácán sor 61.;
3. Is the same GMPt release planned elsewhere in the Community?
Has the same GMPt been notified elsewhere by the same notifier?
Genetically modified plant
Complete name of the recipient or parental plant(s)
Golden Promise/ Malt-607-1001
2. Description of the traits and characteristics which have been introduced or modified, including marker genes and previous modifications:
The new traits of the GM spring barley result in the production of two proteins: the Thaumatin I, which accumulates in the barley grain, and the phosphinothricin acetyltransferase as selection marker.
The Thaumatin I protein, which is naturally produced by the rain forest plant “katemfe” (Thaumatococcus daniellii Benth.), is 2000 – 3000 times sweeter than the sucrose (on weight basis). Thaumatin isolated from katemfe fruits has been approved as dietary food ingredients (E 957) according to EC Directive 94/35/EC. Thaumatin has been qualified as safe by the FAO/JEFCA Committee.
The selectable marker phosphinothricin acetyltransferase has been used for identification of transformed plants.
3. Type of genetic modification:
In case of insertion of genetic material, give the source and intended function of each constituent fragment of the region to be inserted:
Source: Hordeum vulgare
Intended function: To control the endosperm-specific transcription of the Thaumatin I gene during grain filling stage
Source: Hordeum vulgare
Intended function: To target the recombinant protein into the storage vacuoles in barley grains
Fragment: Thaumatin I gene
Source: Thaumatococcus daniellii Benth.
Intended function: To drive production of the product Thaumatin I
Fragment: Transcriptional termination sequence from the 3’ end of the nopaline synthase gene (nos-terminator)
Source: Agrobacterium tumefaciens
Intended function: To terminate transcription of Thaumatin I gene and of the bar gene
Fragment: Promoter of the ubiquitin gene Ubi1 plus its first exon and intron
Source: Zea mays
Intended function: To control constitutive transcription of the bar gene
Fragment: bar gene
Source: Streptomyces hygroscopicus
Intended function: To drive production of the selection marker
6. Brief description of the method used for the genetic modification:
Agrobacterium tumefaciens-mediated transformation of two expression cassettes (for expression of Thaumatin I gene and bar gene, respectively) was uesd according to the method of Tingay et al. (S. Tingay, D. McElroy, R. Kalla, S. Fieg, M. Wang, S. Thornton, R. Brettel. 1997. Agrobacterium tumefaciens-mediated barley transformation. Plant J. 11: 1369-1376)
7. If the recipient or parental plant is a forest tree species, describe ways and extent of dissemination and specific factors affecting dissemination:
- not applicable –
1. Purpose of the release:
Objective of the proposed field trial is to study the behaviour, bearing capacity and agro-technological properties of the transgenic barley line Malt-607-1001 in field-land conditions.
2. Geographical location of the site:
Jánossomorja (0216) in the western region of Győr-Moson-Sopron county in Hungary
3. Size of the site (m2):
maximum 4000 m²
4. Relevant data regarding previous releases carried out with the same GM-plant, if any, specifically related to the potential environmental and human health impacts from the release:
- not applicable –
Environmental Impact and Risk Management
Summary of the potential environmental impact from the release of the GMPts:
According to the notifier, negative effects on the environment are unlikely, as barley is an annual crop that has lost natural seed dispersal mechanisms during domestication; is a self-fertilizing plant with an autogamy rate of about 99% and has a low pollen production.
The additional proteins have no harmful effects on human or animal health.
No significant environmental impacts are expected from these field trials.
Brief description of any measures taken for the management of risks:
-Removal of weeds and wild grasses from the field before the field trials
-Regular inspections during the trials to check weeds and wild grasses
-Containment of the field by 4 m wide edge-strips sowed with conventional barley
-Containment of the field by a protecting fence to minimize animal access
-Isolation distance of at least 35 m to potential pollen recipients (achieved by destruction of the weeds Elymus sp. and wild barley)
-Isolation distance of at least 500 m to conventional barley fields
-Careful harvest and storage of seeds in closed containers
-Destruction of remaining plants tissues by burning (straw) and discing (stubble)
-Destruction of conventional barley from edge-strips in the same way
-Destruction of second growth after the field trial
Summary of foreseen field trial studies focused to gain new data on environmental and human health impact from the release:
The objective of this first field trial is to determine agronomic properties of the transgenic barley, not to gain new data on environmental and human health impact of the release.
European Commission administrative information
Consent given by the Member State Competent Authority: